Korsana Biosciences, Inc. (KRSA) stock
KRSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30591% above fair value
$37.56+2.11 (+5.95%)
Close on Nov 20, 2026Market cap $175.83MP/E –Yield –
Korsana Biosciences free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Korsana Biosciences's free cash flow for the twelve months ending Dec 31, 2022 was -$40.61M. For fiscal 2022 it was -$40.61M. The highest annual figure on record is -$36.52M in fiscal 2021.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | -$40.61M | – |
| FY2021 | Dec 31, 2021 | -$36.52M | – |
| FY2020 | Dec 31, 2020 | -$74.01M | – |
| FY2019 | Dec 31, 2019 | -$109.10M | – |
| FY2018 | Dec 31, 2018 | -$100.94M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$1.43M | – |
| Q1 FY2026 | Mar 31, 2026 | -$1.24M | – |
| Q2 FY2025 | Jun 30, 2025 | -$503.00K | – |
| Q1 FY2025 | Mar 31, 2025 | -$968.00K | – |
| Q4 FY2022 | Dec 31, 2022 | -$7.04M | – |
| Q4 FY2021 | Dec 31, 2021 | -$8.63M | – |
| Q4 FY2020 | Dec 31, 2020 | -$14.08M | – |
| Q3 FY2020 | Sep 30, 2020 | -$15.06M | – |
| Q2 FY2020 | Jun 30, 2020 | -$14.30M | – |
| Q1 FY2020 | Mar 31, 2020 | -$30.59M | – |
| Q4 FY2019 | Dec 31, 2019 | -$22.34M | – |
| Q3 FY2019 | Sep 30, 2019 | -$24.47M | – |
| Q2 FY2019 | Jun 30, 2019 | -$26.22M | – |
| Q1 FY2019 | Mar 31, 2019 | -$36.09M | – |
| Q4 FY2018 | Dec 31, 2018 | -$24.97M | – |
| Q3 FY2018 | Sep 30, 2018 | -$26.46M | – |
| Q2 FY2018 | Jun 30, 2018 | -$22.92M | – |
| Q1 FY2018 | Mar 31, 2018 | -$26.59M | – |
See a number that looks wrong?